Comparative Pharmacology
Head-to-head clinical analysis: CECLOR CD versus CEDAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR CD versus CEDAX.
CECLOR CD vs CEDAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Ceftibuten is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3, thereby inhibiting peptidoglycan cross-linking and leading to cell lysis.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
400 mg orally once daily for 5-10 days.
None Documented
None Documented
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
Terminal elimination half-life: 2.6-3.0 hours; prolonged in renal impairment (up to 10-15 hours in severe impairment)
Renal: ~80% unchanged; biliary/fecal: ~20%
Renal: 92-96% unchanged; biliary/fecal: <5%
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic